14.18MMarket Cap-0.16P/E (TTM)
0.502High0.457Low1.75MVolume0.499Open0.481Pre Close824.20KTurnover6.35%Turnover RatioLossP/E (Static)30.17MShares7.22352wk High0.30P/B12.94MFloat Cap0.43252wk Low--Dividend TTM27.54MShs Float54.000Historical High--Div YieldTTM9.42%Amplitude0.432Historical Low0.471Avg Price1Lot Size
Relmada Therapeutics Stock Forum
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet